Search
 

Wegovy maker takes on compounding pharmacies with $499 per month deal

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

By Allison Bell | March 05, 2025 at 12:19 AM
Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock

The market for GLP-1 agonist weight-loss drugs is giving drug manufacturers a chance to show how hard they’re willing to compete based on price when conditions encourage them to do that.

Novo Nordisk, the maker of Wegovy, the top seller in the GLP-1 drug arena, is trying to chase away the pharmacies that make alternative, “compounded” versions of the drug by offering the real thing for $499 per month for patients who pay cash.

NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2025 ALM Global, LLC. All Rights Reserved.